Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.060
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
1.040
-0.020 (-1.88%)
After-hours: Dec 5, 2025, 6:19 PM EST
Aprea Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 0.49 | 1.5 | 0.58 | - | - | - |
| Revenue Growth (YoY) | -62.75% | 157.63% | - | - | - | - |
| Cost of Revenue | 8.39 | 9.36 | 7.63 | 16.4 | 23.9 | - |
| Gross Profit | -7.91 | -7.86 | -7.04 | -16.4 | -23.9 | - |
| Selling, General & Admin | 5.91 | 6.46 | 8.43 | 20.97 | 13.55 | 14.93 |
| Research & Development | - | - | - | - | - | 37.88 |
| Operating Expenses | 5.91 | 6.46 | 8.43 | 20.97 | 13.55 | 52.81 |
| Operating Income | -13.82 | -14.32 | -15.47 | -37.37 | -37.45 | -52.81 |
| Interest & Investment Income | 0.81 | 1.29 | 1.22 | 0.45 | 0 | 0.22 |
| Currency Exchange Gain (Loss) | -0.03 | 0.07 | -0.04 | 0.28 | 0.32 | -0.89 |
| EBT Excluding Unusual Items | -13.04 | -12.96 | -14.29 | -36.64 | -37.13 | -53.48 |
| Pretax Income | -13.04 | -12.96 | -14.29 | -112.66 | -37.13 | -53.48 |
| Net Income | -13.04 | -12.96 | -14.29 | -112.66 | -37.13 | -53.48 |
| Net Income to Common | -13.04 | -12.96 | -14.29 | -112.66 | -37.13 | -53.48 |
| Shares Outstanding (Basic) | 6 | 6 | 4 | 2 | 1 | 1 |
| Shares Outstanding (Diluted) | 6 | 6 | 4 | 2 | 1 | 1 |
| Shares Change (YoY) | 23.17% | 52.31% | 118.31% | 55.69% | 0.72% | - |
| EPS (Basic) | -2.14 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 |
| EPS (Diluted) | -2.14 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 |
| Free Cash Flow | -13.44 | -13.57 | -12.27 | -25.01 | -37.69 | -41.83 |
| Free Cash Flow Per Share | -2.20 | -2.46 | -3.39 | -15.09 | -35.41 | -39.59 |
| Operating Margin | -2829.92% | -953.00% | -2652.80% | - | - | - |
| Profit Margin | -2670.57% | -862.43% | -2449.59% | - | - | - |
| Free Cash Flow Margin | -2753.58% | -903.26% | -2103.92% | - | - | - |
| EBITDA | -13.8 | -14.3 | -15.46 | -37.37 | -37.43 | -52.78 |
| D&A For EBITDA | 0.02 | 0.02 | 0.01 | 0 | 0.01 | 0.03 |
| EBIT | -13.82 | -14.32 | -15.47 | -37.37 | -37.45 | -52.81 |
Source: S&P Capital IQ. Standard template.
Financial Sources.